Lilly launches employer-connect platform to broaden weight-loss drug access

GoodRx Holdings

05/03/2026 11:01

March 5 (Reuters) - Eli Lilly LLY.N said on Thursday it had rolled out a platform to help employers connect with organizations offering low-cost benefits and comprehensive obesity-care programs, aiming to widen access to its blockbuster weight-loss drug, Zepbound.

Through Lilly Employer Connect platform, its multi-dose weight-loss drug device Zepbound KwikPen will be available to network pharmacies at a discounted price of $449 for all doses

The program provides employees access to weight-loss medicines at lower out-of-pocket costs, and gives employers greater cost predictability and transparency

"By enabling coverage outside traditional benefit designs, we lower barriers to treatment and give employers greater control over how they support employee access to obesity care," said Kevin Hern, senior vice president, Lilly Employer

The platform enables employers to pair access to Lilly's Zepbound KwikPen with a range of services that fit their workforce needs, including in-person or virtual clinical care and behavior-change support

The platform currently works with 15 independent program administrators, including GoodRx GDRX.O, Teladoc Health and Mark Cuban Cost Plus Drug Company, as well as pharmacies across the country, including dispensing pharmacies HealthDyne and CenterWell

Lilly and its Danish rival Novo Nordisk NOVOb.CO have been trying to expand access to their weight-loss treatments and eliminate unapproved, compounded versions, made by combining, mixing or altering drug ingredients

 (Reporting by Mariam Sunny in Bengaluru; Editing by Maju Samuel)

 ((Mariam.ESunny@thomsonreuters.com;))